REGN catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 20, 2026Sponsor estimate | NCT05568459A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care...Regeneron Pharmaceuticals · Hemophilia B | REGNLead | No phase registered | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Nov 20, 2026Sponsor estimateNo phase registeredNCT05568459A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care...Regeneron Pharmaceuticals · Hemophilia BActive, not recruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT04989946Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed...University of Wisconsin, Madison · Prostate CancerActive, not recruitingREGNCollaboratorBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT06623656Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLCWeill Medical College of Cornell University · Carcinoma, Non-Small-Cell LungRecruitingREGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 3, 2026Sponsor estimatePhase 2NCT06421636A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron...Regeneron Pharmaceuticals · Non-Transfusion Dependent Beta-Thalassemia (NTDT)Active, not recruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 4, 2026Sponsor estimatePhase 1NCT06452771A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy AdultsRegeneron Pharmaceuticals · Healthy Volunteers With HyperlipidemiaActive, not recruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 29, 2026Sponsor estimatePhase 2NCT07477704A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have HypercholesterolemiaRegeneron Pharmaceuticals · HypercholesterolemiaActive, not recruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT05347771Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and AdolescentsNational Institute of Allergy and Infectious Diseases (NIAID) · AsthmaActive, not recruitingREGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 2027Sponsor estimate | NCT03694158Investigating Dupilumab's Effect in Asthma by GenotypeBoston Children's Hospital · Asthma | SNYCollaboratorMRKCollaboratorREGNCollaborator | Phase 4 | Active, not recruiting | Locked | Locked | Locked |
| Jan 2, 2027Sponsor estimate | NCT07128641Odronextamab in Low Tumor Volume Advanced FLGottfried von Keudell, MD PhD · Follicular Lymphoma | REGNCollaborator | Phase 2 | Recruiting | Locked | Locked | Locked |
| Jan 15, 2027Sponsor estimate | NCT05608291A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From...Regeneron Pharmaceuticals · Melanoma | REGNLead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Jan 2027Sponsor estimatePhase 4NCT03694158Investigating Dupilumab's Effect in Asthma by GenotypeBoston Children's Hospital · AsthmaActive, not recruitingSNYCollaboratorMRKCollaboratorREGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2, 2027Sponsor estimatePhase 2NCT07128641Odronextamab in Low Tumor Volume Advanced FLGottfried von Keudell, MD PhD · Follicular LymphomaRecruitingREGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 15, 2027Sponsor estimatePhase 3NCT05608291A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From...Regeneron Pharmaceuticals · MelanomaActive, not recruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
- Primary completion Feb 7, 2027Sponsor estimatePhase 4NCT07905547A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic DermatitisSanofi · Atopic DermatitisNot yet recruitingSNYLeadREGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 8, 2027Sponsor estimatePhase 1NCT07526116A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy AdultsRegeneron Pharmaceuticals · Healthy VolunteerRecruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 9, 2027Sponsor estimatePhase 2NCT07175428Safety in Adult Participants With Atrial Fibrillation Who Are Treated With AnticoagulationRegeneron Pharmaceuticals · Atrial Fibrillation (AF)RecruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 17, 2027Sponsor estimatePhase 3NCT07424144An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled...Sanofi · Chronic Rhinosinusitis With Nasal PolypsActive, not recruitingSNYLeadREGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 14 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.